Black checkmark with a sparkle and a curved line underneath on a white background.
Company

Journey Medical Corp

Ticker
DERM
Sector
Industry
Report date
November 14, 2026
Valye AI Score

100

Very high visibility
Recent developments
Recent developments summary

Recent developments include the Q3 2026 earnings call and related reports highlighting the company’s financial results, operational updates, and market context.

Recent developments:
  • Journey Medical reported Q3 2026 revenue of $18.967 million and a net loss of $1.315 million for the quarter ended September 30, 2026, with cash and equivalents of $22.323 million and a current ratio of 1.48 [S2].
  • The company discussed commercial progress and challenges during the Q3 2026 earnings call held in November 2026 [N1].
  • Reports highlighted that Journey Medical’s Q3 2026 results showed a loss and revenue below some expectations, reflecting ongoing operational challenges [N4].
  • The company continues to promote its key dermatological products including Emrosi, Qbrexza, Accutane, Amzeeq, and Zilxi [N2][N3].
Overview

Journey Medical Corp is a pharmaceutical company focused on dermatology, marketing eight FDA-approved prescription drugs in the U.S. The company’s products address significant dermatological conditions including rosacea (Emrosi, Zilxi), acne (Accutane, Amzeeq, Targadox), primary axillary hyperhidrosis (Qbrexza), fungal infections (Exelderm), and pruritus (Anti-itch Product). Emrosi, approved in November 2024, is a novel oral minocycline extended release capsule for rosacea. The company’s strategy includes commercial execution of existing products, lifecycle management, out-licensing, and growth through acquisitions and licensing. Journey Medical is a controlled subsidiary of Fortress Biotech and is listed on NASDAQ under ticker DERM.

Executive summary

Journey Medical Corp is a commercial-stage pharmaceutical company specializing in FDA-approved dermatological prescription products marketed in the U.S. Its portfolio includes eight key products targeting conditions such as rosacea, acne, hyperhidrosis, fungal infections, and pruritus. The company reported Q3 2026 revenue of $18.967 million and a net loss of $1.315 million, with cash and equivalents of $22.323 million as of September 30, 2026. The company is a subsidiary of Fortress Biotech and is listed on NASDAQ under ticker DERM. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.

Scenarios for DERM

Bull case model:

Journey Medical’s portfolio addresses large dermatological markets with millions of prescriptions annually, including rosacea, acne, and hyperhidrosis. Emrosi’s FDA approval and patent protection through 2039 provide a differentiated oral treatment option for rosacea. The company’s commercial execution and lifecycle management of products like Qbrexza, Accutane, Amzeeq, and Zilxi support revenue growth. Expansion through new product launches such as the Anti-itch Product and potential acquisitions could enhance the product pipeline and market reach.

Bear case model:

Journey Medical operates in competitive dermatology markets with established players and generic alternatives. The company reported a net loss in Q3 2026, indicating ongoing profitability challenges. Dependence on a limited number of products for revenue exposes the company to market and regulatory risks. Commercial execution risks, reimbursement challenges, and potential delays or failures in product launches or acquisitions could impact financial performance. The company’s liquidity, while adequate, requires careful management to support growth initiatives.

Moat:

Journey Medical’s moat derives from its portfolio of FDA-approved dermatological products with patent protection extending through 2030 to 2039, including Emrosi’s patents through 2039. The company leverages proprietary drug delivery technologies such as Multiple Unit Pellet System for Emrosi and MST technology for topical foams Amzeeq and Zilxi. Its focused commercial team and established presence in dermatology markets, combined with intellectual property and regulatory approvals, create barriers to entry. The company’s strategy to augment its portfolio through licensing and acquisitions supports sustained competitive positioning.

Risks overview
Risks summary
Journey Medical faces risks from competitive pressures, profitability challenges, product concentration, regulatory and commercial execution uncertainties, and liquidity management.
Risks details:

• Market Competition: The dermatology pharmaceutical market is competitive with established brands and generic alternatives that may limit market share and pricing power.
• Profitability Challenges: The company reported net losses in recent quarters, reflecting ongoing challenges in achieving sustained profitability.
• Product Concentration: Revenue depends heavily on a limited number of key products, increasing vulnerability to market or regulatory changes affecting those products.
• Regulatory and Commercial Risks: Risks include potential delays in product launches, reimbursement issues, and challenges in commercial execution that could affect revenue growth.
• Liquidity and Financing: While current liquidity ratios indicate adequate short-term financial health, the company needs to manage cash and financing carefully to support operations and growth.

FINAL FORECAST FOR DERM

Final take one line
Journey Medical Corp is a dermatology-focused pharmaceutical company with a well-defined product portfolio and detailed financial disclosures, facing typical industry execution and market risks.
Final take 12 to 24 month view

Business trends: Continued commercialization of FDA-approved dermatology products addressing large markets such as rosacea, acne, and hyperhidrosis; ongoing efforts to expand product portfolio through acquisitions and licensing.
Execution milestones: Progress in commercial sales of Emrosi and other key products; launch of Anti-itch Product; management of profitability and operational efficiency; maintaining patent protections.
Key risks: Competitive market pressures; challenges in achieving sustained profitability; dependence on a limited product portfolio; regulatory and reimbursement uncertainties; liquidity management.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

100
LLM visibility overview
LLM Visibility known facts
  • Journey Medical Corp is a commercial-stage pharmaceutical company focused on selling and marketing FDA-approved prescription drugs for dermatological conditions in the U.S.
  • The company is a controlled subsidiary of Fortress Biotech, Inc.
  • Journey Medical's product portfolio includes eight FDA-approved prescription drugs marketed in the U.S., including Emrosi, Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm, Targadox, Luxamend, and an Anti-itch Product.
  • Emrosi is an oral minocycline hydrochloride extended release capsule approved in November 2024 for inflammatory lesions of rosacea in adults, with sales promotion starting April 2025.
  • Qbrexza is a topical anticholinergic cloth approved in June 2018 for primary axillary hyperhidrosis, launched May 2021.
  • Accutane is an oral isotretinoin drug for severe recalcitrant nodular acne, licensed in July 2020 and launched March 2021.
  • Amzeeq and Zilxi are topical minocycline foams approved for acne and rosacea, respectively, launched in January 2022.
  • Exelderm is a broad-spectrum antifungal cream and solution for fungal skin infections.
  • The Anti-itch Product is a non-steroidal, antihistamine-free topical treatment for pruritus and related conditions, planned for launch in first half 2026.
  • The company’s strategy includes commercial execution of existing products, lifecycle management, out-licensing, and growth through acquisitions and licensing.
  • Rosacea affects millions in the U.S. and worldwide; Emrosi and Zilxi target this market with differentiated minocycline formulations.
  • The company reported Q3 2026 financials with revenue of $18.967 million and a net loss of $1.315 million for the quarter ending September 30, 2026.
  • Cash and cash equivalents were $22.323 million as of September 30, 2026, with current assets of $79.264 million and current liabilities of $53.52 million, yielding a current ratio of 1.48 and a cash ratio of 0.42.
  • Shares outstanding as of November 12, 2026, include 6 million Class A and 22.23 million common shares.
  • Journey Medical is listed on NASDAQ Capital Market under ticker DERM.
  • Recent news includes detailed Q3 2026 earnings call transcripts and reports discussing the company’s financial results and operational updates in November 2026.
  • The company’s products address significant dermatological markets including rosacea, acne, hyperhidrosis, fungal infections, and pruritus, with prescription volumes in millions according to Symphony Health data.
  • Journey Medical joined the Russell 2000 and Russell 3000 indices in June 2025.
  • The company maintains a website www.jmcderm.com where SEC filings and reports are available.
  • Emrosi has three Orange Book-listed patents extending through January 2039; Zilxi has nine patents through October 2030; Amzeeq has twelve patents through September 2037; Qbrexza has eight patents through February 2033.
Sources
Sources - Context summary

Generated 2026-11-15

Sources - Earning calls
  • N1
Sources - Other context
  • S1
  • S2
Sources - SEC Filings
  • S1 | 2026-03-25 | 10-K
  • S2 | 2026-11-12 | 10-Q
Sources - News headlines
  • N1 | 2026-11-13 | www.nasdaq.com | Journey Medical (DERM) Q3 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/journey-medical-derm-q3-2026-earnings-call-transcript
  • N2 | 2026-11-12 | www.nasdaq.com | What Journey Medical (DERM) Said on Its Q3 Earnings Call | https://www.nasdaq.com/articles/what-journey-medical-derm-said-its-q3-earnings-call
  • N3 | 2026-11-12 | www.nasdaq.com | Journey Medical (DERM) Reports Q3 Earnings: What Key Metrics Have to Say | https://www.nasdaq.com/articles/journey-medical-derm-reports-q3-earnings-what-key-metrics-have-say
  • N4 | 2026-11-12 | www.nasdaq.com | Journey Medical Corporation (DERM) Reports Q3 Loss, Lags Revenue Estimates | https://www.nasdaq.com/articles/journey-medical-corporation-derm-reports-q3-loss-lags-revenue-estimates
  • N5 | 2026-11-09 | www.nasdaq.com | Ocular Therapeutix (OCUL) Reports Q3 Loss, Lags Revenue Estimates | https://www.nasdaq.com/articles/ocular-therapeutix-ocul-reports-q3-loss-lags-revenue-estimates
  • N6 | 2026-11-06 | www.nasdaq.com | VAXART, INC. (VXRT) Reports Q3 Loss, Beats Revenue Estimates | https://www.nasdaq.com/articles/vaxart-inc-vxrt-reports-q3-loss-beats-revenue-estimates
  • N7 | 2026-11-04 | www.nasdaq.com | Will Journey Medical Corporation (DERM) Report Negative Q3 Earnings? What You Should Know | https://www.nasdaq.com/articles/will-journey-medical-corporation-derm-report-negative-q3-earnings-what-you-should-know
  • N8 | 2026-10-23 | www.nasdaq.com | Korro Bio, Inc. (KRRO) Surges 29.7%: Is This an Indication of Further Gains? | https://www.nasdaq.com/articles/korro-bio-inc-krro-surges-297-indication-further-gains
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine